Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0001485

Rivastigmine for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H22N2O2 · C4H6O6
CAS Number:
129101-54-8
Molecular Weight:
400.42
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

rivastigmine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

InChI key

GWHQHAUAXRMMOT-RWALOXMOSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Rivastigmine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001516

Rivastigmine hydrogen tartrate, European Pharmacopoeia (EP) Reference Standard

Y0001515

Rivastigmine impurity D, European Pharmacopoeia (EP) Reference Standard

1604811

Rivastigmine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1604836

Rivastigmine, United States Pharmacopeia (USP) Reference Standard

1604825

Rivastigmine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1604847

Rivastigmine tartrate R-isomer, United States Pharmacopeia (USP) Reference Standard

1604869

Rivastigmine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1604858

Rivastigmine tartrate, United States Pharmacopeia (USP) Reference Standard

1604870

Rivastigmine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1604961

Rivastigmine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1604950

Rivastigmine Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR1867

Rivastigmine Hydrogen Tartrate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2034

Rivastigmine Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2032

Rivastigmine Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2031

Rivastigmine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2029

Rivastigmine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2033

Rivastigmine Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2030

Rivastigmine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

hcodes

H300,H411

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Chronic 2

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cassandra Richardson et al.
International journal of geriatric psychiatry, 28(12), 1312-1317 (2013-04-16)
A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim of this study was to assess the potential influence of AChEIs on blood
Zhen-Zhen Yang et al.
International journal of pharmaceutics, 452(1-2), 344-354 (2013-05-18)
Alzheimer's disease (AD) is a common progressive neurodegenerative disorder associated with cholinergic neurons degeneration. The blood-brain barrier (BBB) not only provides protection for the brain but also hinders the treatment and diagnosis of this neurological disease, because the drugs must
George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service